SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 232 filers reported holding SAGE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,174 | -81.2% | 300 | -57.1% | 0.00% | -77.8% |
| Q2 2023 | $32,914 | +12.1% | 700 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $29,372 | +112869.2% | 700 | 0.0% | 0.01% | – |
| Q4 2022 | $26 | -99.9% | 700 | 0.0% | 0.00% | – |
| Q3 2022 | $27,000 | +22.7% | 700 | 0.0% | 0.00% | – |
| Q2 2022 | $22,000 | -4.3% | 700 | 0.0% | 0.00% | – |
| Q1 2022 | $23,000 | -79.5% | 700 | -73.6% | 0.00% | – |
| Q4 2021 | $112,000 | -4.3% | 2,650 | 0.0% | 0.00% | – |
| Q3 2021 | $117,000 | -22.0% | 2,650 | 0.0% | 0.00% | – |
| Q2 2021 | $150,000 | -24.2% | 2,650 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $198,000 | -15.7% | 2,650 | -2.8% | 0.00% | 0.0% |
| Q4 2020 | $235,000 | +2.2% | 2,725 | -27.8% | 0.00% | – |
| Q3 2020 | $230,000 | +29.9% | 3,775 | -11.7% | 0.00% | – |
| Q2 2020 | $177,000 | +55.3% | 4,275 | +7.5% | 0.00% | – |
| Q1 2020 | $114,000 | – | 3,975 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |